First Cohort Results In Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence Of Therapeutic Effect On Fibrosis And Inflammation In Nash With Advanced Fibrosis
4/1/2014 11:03:25 AM
NORCROSS, Ga., March 31, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that results from the first cohort of its Phase 1 trial show that GR-MD-02 had an effect on biomarkers that suggest a therapeutic effect on fibrosis, inflammation, and cellular injury. The first-in-man study, which enrolled eight patients in the first cohort, is evaluating the safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of its galectin-inhibiting drug GR-MD-02 when administered to patients with fatty liver disease (NASH) with advanced fibrosis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by